Brief: Suven Life Sciences Completes Patient Enrollment In Global Phase-3 Masupirdine Study
03/09/2026 10:19
BRIEF-Suven Life Sciences Completes Patient Enrollment In Global Phase-3 Masupirdine Study Sept 3 (Reuters) - Suven Life Sciences Ltd SUVP.NS:
SUVEN LIFE SCIENCES - COMPLETES PATIENT ENROLLMENT IN GLOBAL PHASE-3 MASUPIRDINE STUDY
Source text: ID:nBSE2L7Ch7
Further company coverage: SUVP.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Patient Enrollment In Global Phase-3 Masupirdine Study
India's Suven Life Sciences gains after Masupirdine Phase-3 study completes patient enrollment
Brief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant